iRhythm Technologies (NASDAQ:IRTC) Announces Earnings Results

06 Aug 2026, 22:26 by Sarita Garza · The Markets Daily

iRhythm Technologies (NASDAQ:IRTC – Get Free Report) issued its quarterly earnings results on Thursday. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.62, FiscalAI reports. iRhythm Technologies had a negative net margin of 3.53% and a negative return on equity of 10.26%. The business had revenue of $224.17 million for the quarter, compared to analysts’ expectations of $219.30 million.

Here are the key takeaways from iRhythm Technologies’ conference call:

Q2 revenue rose 20.1% to $224.2 million, marking the seventh consecutive quarter of more than 20% growth. Adjusted EBITDA margin reached 19.3%, free cash flow was a record $37.5 million, and adjusted net income improved to $19.3 million.
iRhythm raised its 2026 outlook to $880 million-$890 million in revenue and a 13%-14% adjusted EBITDA margin, citing sustained volume growth, operating efficiencies, and disciplined expense management.
The pending VitalConnect acquisition is intended to broaden iRhythm’s MCT offering and add capabilities in inpatient monitoring, hospital-to-home care, remote patient monitoring, and multi-vital sensing. Management expects revenue contribution beginning in 2027 and believes the combined company can reach its previously stated 15% adjusted EBITDA margin target in 2027.
FDA clearance of iRhythm’s third-generation algorithm could reduce technician review time by up to 50% and generate approximately $100 million in cumulative cost savings over five years after its planned first-half 2027 launch.
Key execution and regulatory risks remain, including the pending FDA warning-letter resolution, HSR review and integration of VitalConnect, and continued uncertainty around the timing of Zio MCT clearance. The company also agreed to pay $50 million to settle litigation with Baxter, while a June cybersecurity incident involved data exfiltration despite no reported material operational or financial impact.

iRhythm Technologies Stock Up 2.9%

Shares of IRTC stock traded up $3.62 on Thursday, reaching $128.12. 1,205,295 shares of the stock were exchanged, compared to its average volume of 607,483. The company has a current ratio of 5.17, a quick ratio of 4.98 and a debt-to-equity ratio of 4.03. The business’s 50 day moving average price is $114.51 and its 200 day moving average price is $124.83. The company has a market capitalization of $4.21 billion, a price-to-earnings ratio of -148.98 and a beta of 1.30. iRhythm Technologies has a twelve month low of $100.85 and a twelve month high of $212.00.

Insider Transactions at iRhythm Technologies

In other iRhythm Technologies news, Director Abhijit Y. Talwalkar acquired 5,312 shares of the stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $10.71 per share, with a total value of $56,891.52. Following the transaction, the director owned 25,611 shares in the company, valued at $274,293.81. The trade was a 26.17% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.98% of the stock is owned by company insiders.

Institutional Investors Weigh In On iRhythm Technologies

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Corient Private Wealth LLC lifted its position in shares of iRhythm Technologies by 12.1% during the 4th quarter. Corient Private Wealth LLC now owns 1,764 shares of the company’s stock worth $313,000 after buying an additional 191 shares during the last quarter. Fuller & Thaler Asset Management Inc. raised its stake in iRhythm Technologies by 7.4% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 639,423 shares of the company’s stock worth $113,459,000 after acquiring an additional 44,175 shares in the last quarter. XTX Topco Ltd acquired a new stake in iRhythm Technologies during the 4th quarter worth $855,000. RTW Investments LP purchased a new stake in iRhythm Technologies in the fourth quarter valued at $209,732,000. Finally, Occudo Quantitative Strategies LP lifted its position in iRhythm Technologies by 103.8% in the fourth quarter. Occudo Quantitative Strategies LP now owns 16,484 shares of the company’s stock valued at $2,925,000 after acquiring an additional 8,395 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on IRTC. Canaccord Genuity Group cut their target price on shares of iRhythm Technologies from $180.00 to $152.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Truist Financial dropped their price target on shares of iRhythm Technologies from $174.00 to $160.00 and set a “buy” rating for the company in a research note on Thursday, July 16th. Wells Fargo & Company cut their price objective on iRhythm Technologies from $200.00 to $180.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Citigroup increased their price objective on iRhythm Technologies from $155.00 to $157.00 and gave the company a “buy” rating in a research note on Monday, May 4th. Finally, Needham & Company LLC lifted their target price on iRhythm Technologies from $254.00 to $255.00 and gave the company a “buy” rating in a report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, iRhythm Technologies has an average rating of “Moderate Buy” and a consensus target price of $184.71.

View Our Latest Stock Report on IRTC

About iRhythm Technologies

(Get Free Report)

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.